Evaluating the effect of hemodialysis modality on inflammation

Evaluating the effect of hemodialysis modality on NETosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN61455095

Enrollment

Registered

2025-01-21

Start date

2023-05-01

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients Nutritional, Metabolic, Endocrine

Interventions

Initially, the study was designed to evaluate NETosis activation and serum markers after 1 month of treatment with each modality (hemodiafiltration [HDF] and high-flux hemodialysis [HD]). However, due

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Hemodialysis patients Added 06/06/2025: 10 healthy participants will be recruited as a control group for both study arms

Exclusion criteria

Exclusion criteria: Patients with diseases that can affect NETosis such as autoimmunity, hemato-oncology, HIV and hepatitis C, B positive

Design outcomes

Primary

Measure	Time frame
NETosis activation and markers peptidylarginine deiminase 4 (PAD4), neutrophil elastase (NE), myeloperoxidase (MPO), histone H3 and dsDNA were measured using flow cytometry, and serum levels of citrullinated histone H3 (citHIS), MPO and NE were measured using ELISA, before and after treatment	—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Israel

Contacts

Public ContactEtty Kruzel-Davila

ETTYK@gmc.gov.il+972-4-9107619

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026